Linagliptin (below structure, BI-1356, trade name Tradjenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion
from pancreatic beta cells in the presence of normal and elevated blood
glucose levels. GLP-1 also reduces glucagon
secretion from pancreatic alpha cells, resulting in a reduction in
hepatic glucose output. Thus, linagliptin stimulates the release of
insulin in a glucose-dependent manner and decreases the levels of
glucagon in the circulation.
Now Health Canada approves....
No comments:
Post a Comment